| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Vigilor targets adenylate cyclase as an inhibitor. As a nootropic agent, it is believed to enhance cognitive functions such as memory and learning. It is a potent psychostimulant and has been used in the treatment of various neurological disorders.
|
|---|---|
| ln Vitro |
In Arabidopsis wild-type seedlings, fipexide (50 μM; for 15 days) hydrochloride exhibits a simple structure with regions of active division and epidermal regions with completely enlarged cells [2].
In vitro, Vigilor acts as a psychoactive compound belonging to the piperazine chemical class. Its nootropic properties are believed to enhance cognitive functions such as memory and learning. Its activity is assessed using receptor binding and neurotransmitter release assays. |
| ln Vivo |
Fipexide (10 mg/kg; oral; 5–10 days) Hydrochloride totally removes convulsion-related memory impairments [3].
In vivo, Vigilor was used in Italy and France for the treatment of senile dementia. It acts as a nootropic agent and psychostimulant. Due to undesirable side effects including fever and hepatitis, it is no longer in common use. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Vigilor are performed using membrane preparations expressing adenylate cyclase or other potential targets. The compound's ability to inhibit adenylate cyclase activity is measured by quantifying cAMP production. Binding affinity to neurotransmitter receptors is assessed using radioligand competition binding assays.
|
| Cell Assay |
In vitro cellular assays for Vigilor are performed using neuronal cell lines. Cells are treated with the compound, and neurotransmitter release, cAMP levels, or other signaling pathways are measured. The compound's effects on cellular function are quantified to characterize its mechanism of action.
|
| Animal Protocol |
Animal/Disease Models: Kindred rat [3]
Doses: 10 mg/kg Route of Administration: Oral; 5-10 day Experimental Results: Complete elimination of memory defects caused by ignition. Antagonizes the amnestic effects of pentylenetetrazol (PTZ) ignition. In vivo animal experiments for Vigilor are not extensively documented. As a nootropic agent, in vivo studies would typically involve administration to animal models of cognitive impairment. Efficacy would be assessed by measuring performance in behavioral tests such as the Morris water maze or novel object recognition. |
| ADME/Pharmacokinetics |
Vigilor has a molecular weight of 425.31 and molecular formula C₂₀H₂₂Cl₂N₂O₄. Its IUPAC name is 1-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-2-(4-chlorophenoxy)ethanone; hydrochloride. It appears as a white to off-white solid powder.
|
| Toxicity/Toxicokinetics |
Toxicological data for Vigilor are available from its clinical use. Undesirable side effects include fever and hepatitis, which led to its discontinuation. The compound is intended for research purposes only and is not for human use.
|
| References |
|
| Additional Infomation |
1-[4-(1,3-benzodioxacyclopenten-5-ylmethyl)-1-piperazinyl]-2-(4-chlorophenoxy)acetone is a member of the benzodioxacyclopentene class of compounds.
Vigilor is also known as Fipexide hydrochloride and Attentil. It is a psychoactive drug of the piperazine class developed in Italy in 1983 for the treatment of senile dementia. It is no longer in common use due to adverse side effects. This product is for research use only. |
| Molecular Formula |
C20H21N2O4CL.HCL
|
|---|---|
| Molecular Weight |
425.30568
|
| Exact Mass |
424.096
|
| CAS # |
34161-23-4
|
| Related CAS # |
Fipexide;34161-24-5
|
| PubChem CID |
3351
|
| Appearance |
White to off-white solid powder
|
| Density |
1.342g/cm3
|
| Boiling Point |
559.3ºC at 760 mmHg
|
| Flash Point |
292.1ºC
|
| LogP |
3.469
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
492
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
BFUJHVVEMMWLHC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H21ClN2O4/c21-16-2-4-17(5-3-16)25-13-20(24)23-9-7-22(8-10-23)12-15-1-6-18-19(11-15)27-14-26-18/h1-6,11H,7-10,12-14H2
|
| Chemical Name |
1-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-2-(4-chlorophenoxy)ethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3512 mL | 11.7561 mL | 23.5123 mL | |
| 5 mM | 0.4702 mL | 2.3512 mL | 4.7025 mL | |
| 10 mM | 0.2351 mL | 1.1756 mL | 2.3512 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
